Sigilon Therapeutics Overview

Sigilon Therapeutics Research & Development

Research & Development expenses for SGTX.

Quarterly R&D Expenses

$7.45M

↓ 37.27% YoY

As of Jun 30, 2023

Annual R&D Expenses (TTM)

$29.37M

↓ 46.44% YoY

Trailing 12 months ending Jun 30, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin